The pharma launch market has settled the question of which tools to use. It still hasn't answered the only question that decides the launch: who is in the room. The short version: The platforms are real and the value is there, but the edge was never in owning the software. The gap nobody sells into is the person who runs it against your molecule, with authority to act. The 2027 launches that look effortless will belong to whoever put control back in the room. Six posts ago I

We're probably at the peak of the AI hype cycle. Your teams have moved beyond experimenting with ChatGPT—they're now integrating AI into...